ONIRO is a breakthrough, patent-pending, clinically tested nutraceutical designed for optimum weight management, heart health and glucose homeostasis. ONIRO manages caloric uptake through carb control by inhibiting carbohydrate-digesting enzymes and glucose uptake in the small intestine. ONIRO which is a proprietary extract of onions cultivated in the nutrient-rich land of Jeju Island (S. Korea), helps improve heart biomarkers and reduce weight by managing carbohydrate digestion and uptake in the small intestine.
ONIRO is produced in a manner to ensure the highest level of onion-derived bioactive compounds. This is achieved by controlling the pH (for optimum stability of health-beneficial flavonoids) and the temperature (for optimum creation of ARCs – Amadori Rearrangement Compounds).
Backed by a human clinical trial and in vivo pre-clinical studies which have proven its significant health benefits, and possessing a comprehensive safety profile, ONIRO leads the list of proprietary, branded ingredients by offering competitive pricing at the recommended, efficacious dose.
ONIRO Features & Benefits:
o ONIRO is produced by onions that are grown under strict agronomic conditions in the nutrient rich soils of Jeju Island in S. Korea.
o ONIRO is a well-defined modulator of carbohydrate uptake in the small intestine.
o ONIRO is produced using a proprietary extraction method that ensures the maximum
level of bioactive compounds, such as flavonoids and ARCs.
o Metabolic Syndrome Management
o Fat Reduction
o Cholesterol & LDL Cholesterol Reduction
o Carbohydrate Hydrolyzing Enzyme Inhibition
- Intake 300mg 3 times a day for 12 weeks for 56 subjects
- Evaluation of the distribution of abdominal fat through CT
- Evaluation of fat distribution, fat mass, and body mass through DEXA
Table 1: Fat percentage, fat mass, and lean body mass by DEXA Evaluation of placebo and test groups at baseline and 12-week follow-up.
- Significant reduction in body fat and fat mass
Table 2: Abdominal fat areas by CT Evaluation of placebo and test groups at baseline and the 12-week follow-up.
- First Lumbar Vertebra (L1): Significant reduction in whole, visceral, and subcutaneous fat.
- Fourth Lumbar Vertebra (L4): Significant reduction in whole and subcutaneous fat.